Introduction {#s1}
============

Facing an immediate crisis by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which has been called the once in a century pathogen, requires a global response ([@B1]). The disease caused by this virus has been named "coronavirus disease 2019" (COVID-19) by the World Health Organization (WHO). As of now, more than 180 countries have reported COVID-19 patients. Given the increasing number of countries infected with SARS-CoV-2, WHO finally classified COVID-19 as a pandemic on March 11, 2020 ([@B2]). The SARS-CoV-2 virus is a beta-coronavirus, belonging to the same coronavirus family as the Middle East Respiratory Syndrome virus (MERS-CoV) and SARS-CoV. MERS-CoV and SARS-CoV were previously responsible for respiratory syndrome outbreaks. However, COVID-19 is the first virus of the coronavirus family to cause a pandemic ([@B3]).

COVID-19 started in China in December 2019 when a cluster of patients with pneumonia of unknown origin were identified in the city of Wuhan. Since then, it has infected hundreds of thousands of people around the world and resulted in more than 539,900 deaths up to this date ([@B4]). Despite governmental travel restrictions in many countries, the confirmed number of new cases has been rising globally. The international community has asked for at least 675 million US dollars to use for preparedness and protection of states with weaker health systems ([@B5]).

In the previous two outbreaks of coronaviral respiratory illness, namely Severe Acute Respiratory Illness (SARS) and Middle East Respiratory Illness (MERS), gender-based differences in mortality were observed. In SARS, mortality risk was twice as high in younger males compared to younger females, but this difference in mortality decreased with older age. Additionally, the case fatality rate observed in males was twice that of females in MERS ([@B6]). The effect of sex on COVID-19 mortality was unknown. In our systematic review, we compared male and female mortality risk for COVID-19.

The novelty of COVID-19 has raised many questions about the epidemiology of the disease, clinical and laboratory methods of diagnosis, as well as therapeutic measures. Many observational studies have been dealing with these features separately. Further combined systematic reviews are needed, to understand the role of sex in COVID-19 associated mortality. In this meta-analysis study, we reviewed the published literature from January 1, 2019 to May 29, 2020 to provide a comprehensive overview of COVID-19.

Methods {#s2}
=======

Search Strategy
---------------

We searched Pubmed/Medline, Embase, Web of Science, and the Cochrane Library for studies published from January 1, 2019 to May 29, 2020. The search strategy was based on the following key-words: COVID-19, severe acute respiratory syndrome coronavirus 2, novel coronavirus, SARS-CoV-2, nCoV disease, SARS2, COVID19, Wuhan coronavirus, Wuhan seafood market pneumonia virus, 2019-nCoV, coronavirus disease-19, coronavirus disease 2019, 2019 novel coronavirus and Wuhan pneumonia. Lists of references of selected articles and relevant review articles were hand-searched to identify further studies. This study was conducted and reported according to the PRISMA guidelines ([@B7]). The study did not require Institutional Review Board approval.

Study Selection
---------------

The records found through database searching were merged and the duplicates were removed using EndNote X7 (Thomson Reuters, New York, NY, USA). Two reviewers (YF and PJ) independently screened the records by title and abstract to exclude those not related to the current study. The full texts of potentially eligible records were retrieved and evaluated by a third reviewer (AT). Included studies met the following inclusion criteria: (i) patients were confirmed and diagnosed with RT-PCR as suggested by WHO; (ii) The raw data for clinical, radiological and laboratory findings were included; and (iii) the outcomes were addressed. Studies with insufficient information about patients\' characteristics and outcomes were excluded. Case reports, reviews, and animal studies were also excluded. Only studies written in English were selected.

Data Extraction and Quality Assessment
--------------------------------------

A data extraction form was designed by two reviewers (AZ and SH). These reviewers extracted the data from all eligible studies and differences were resolved by consensus. The following data was extracted: first author name; year of publication; type of study; country(ies) where the study was conducted; distribution of age and sex in the population; number of patients investigated; data for clinical, radiological, and laboratory findings; and outcomes.

Data Synthesis and Analysis
---------------------------

Statistical analyses were performed with STATA (version 14, IC; Stata Corporation, College Station, TX, USA). The pooled frequency with 95% confidence intervals (CI) was assessed using random effect model. The between-study heterogeneity was assessed by Cochran\'s Q and the I2 statistic. Publication bias was assessed statistically by using Begg\'s and Egger\'s tests (*p* \< 0.05 was considered indicative of statistically significant publication bias).

Quality Assessment
------------------

The checklist provided by the Joanna Briggs Institute (JBI) was used to perform quality assessment ([@B8]).

Results {#s3}
=======

The search yielded 1,223 publications, of which 280 potentially eligible studies were identified for full-text review, resulting in 34 studies fulfilling the inclusion criteria ([Figure 1](#F1){ref-type="fig"}) ([Table 1](#T1){ref-type="table"}). A total of 5,057 patients were included, of which the mean age was 49.0 years. Based on JBI tool, the included studies had a low risk of bias.

![Flow chart of study selection for inclusion in the systematic review and meta-analysis.](fmed-07-00459-g0001){#F1}

###### 

Characteristics of the included studies.

  **First author**           **Country**   **Published time**   **Type of study**   **Mean age**   **Male/female**   **Nationality**   **No. of patients**   **Diagnostic methods**
  -------------------------- ------------- -------------------- ------------------- -------------- ----------------- ----------------- --------------------- ------------------------
  Hui et al. ([@B9])         China         14, Jan, 2020        Case series         NR             NR                Chinese           41                    RT-PCR/CT-scan
  Xia et al. ([@B10])        China         26, Feb, 2020        Case series         54.5           21M, 9F           Chinese           30                    RT-PCR
  Xu et al. ([@B11])         China         13, Feb, 2020        Case series         41             M35, F27          Chinese           62                    RT-PCR
  Zhang et al. ([@B12])      China         7, Feb, 2020         Case series         NR             NR                Chinese           178                   RT-PCR
  To et al. ([@B13])         China         12, Feb, 2020        Case series         62.5           7M, 5F            Chinese           12                    RT-PCR
  Zou et al. ([@B14])        China         19, Feb, 2020        Correspondence      59             9M,9F             Chinese           18                    RT-PCR
  Hoehl et al. ([@B15])      Germany       3, Mar, 2020         Correspondence      35             NR                German            126                   RT-PCR/CT-scan
  Pan et al. ([@B16])        China         24, Feb, 2020        Correspondence      NR             NR                Chinese           82                    RT-PCR/CT-scan
  Tang et al. ([@B17])       China         19, Feb, 2020        Cross-sectional     54             98M, 85F          Chinese           183                   RT-PCR
  Chung et al. ([@B18])      China         4, Feb, 2020         Cross-sectional     51             M13, F8           Chinese           21                    RT-PCR/CT-scan
  Fang et al. ([@B19])       China         19, Feb, 2020        Cross-sectional     45             29M, 22F          Chinese           51                    RT-PCR/CT-scan
  Guan et al. ([@B20])       China         28, Feb, 2020        Cross-sectional     47             640M,459F         Chinese           1099                  RT-PCR/CT-scan
  Huang et al. ([@B21])      China         24, Jan, 2020        Cross-sectional     49             30M,11F           Chinese           41                    RT-PCR
  Kui et al. ([@B22])        China         7, Feb, 2020         Cross-sectional     57             61M,76F           Chinese           137                   RT-PCR
  Li et al. ([@B23])         China         29, Jan, 2020        Cross-sectional     52             M238, F187        Chinese           425                   RT-PCR/CT-scan
  Liu et al. ([@B24])        China         9, Feb, 2020         Cross-sectional     53.6           8M, 4F            Chinese           12                    RT-PCR/CT-scan
  Wang et al. ([@B25])       China         7, Feb, 2020         Cross-sectional     56             75M, 63F          Chinese           138                   RT-PCR/CT-scan
  Wu et al. ([@B26])         China         29, Feb, 2020        Cross-sectional     46             39M, 41F          Chinese           80                    RT-PCR
  Zhang et al. ([@B27])      China         19, Feb, 2020        Cross-sectional     57             71M,69F           Chinese           140                   RT-PCR
  Ai et al. ([@B28])         China         26, Feb, 2020        Cross-sectional     48.5           M467, F547        Chinese           1014                  RT-PCR/CT scan
  Pan et al. ([@B29])        China         13, Feb, 2020        Cross-sectional     40             6M, 15F           Chinese           21                    RT-PCR/CT-scan
  Shi et al. ([@B30])        China         24, Feb, 2020        Cross-sectional     49.5           42M, 39F          Chinese           81                    RT-PCR/CT-scan
  Yang et al. ([@B31])       China         21, Feb, 2020        Cross-sectional     59.7           35M, 17F          Chinese           52                    RT-PCR
  Bajema et al. ([@B32])     China         4, Feb, 2020         Cross-sectional     NR             115M, 95F         Chinese           210                   RT-PCR/CT-scan
  Bernheim et al. ([@B33])   China         20, Feb, 2020        Cross-sectional     45.3           61M, 60F          Chinese           121                   RT-PCR
  Chen et al. ([@B34])       China         15, Feb, 2020        Cross-sectional     55.5           67M, 32F          Chinese           99                    RT-PCR
  Pan et al. ([@B35])        China         13, Feb, 2020        Cross-sectional     45             33M, 30F          Chinese           63                    RT-PCR
  Xu et al. ([@B36])         China         21, Feb, 2020        Cross-sectional     44             29M, 21F          Chinese           50                    RT-PCR/CT-scan
  Xu et al. ([@B37])         China         28, Feb, 2020        Cross-sectional     50             39M, 51F          Chinese           90                    RT-PCR
  Chang et al. ([@B38])      China         7, Feb, 2020         Research letter     34             10M, 3F           Chinese           13                    RT-PCR/CT-scan
  Chen et al. ([@B39])       China         26, Feb, 2020        Research letter     NR             NR                Chinese           85                    RT-PCR/CT-scan
  Kwok et al. ([@B40])       China         7, Feb, 2020         Research letter     59.8           9M, 5F            Chinese           14                    RT-PCR/CT-scan
  Hansen et al. ([@B41])     Norway        23 April, 2020       Cross-sectional     72.5           28M,14F           Norwegian         42                    RT-PCR/CT-scan
  Yu et al. ([@B42])         China         14, May, 2020        Cross-sectional     64             139 M, 87 F       Chinese           226                   RT-PCR/CT-scan

Clinical Manifestations and Comorbidities
-----------------------------------------

The most common signs and symptoms were fever (83.0%, CI 77.5--87.6), cough (65.2%, CI 58.6--71.2), dyspnea (27.4%, CI 19.6--35.2), myalgia/fatigue (34.7%, CI 26.0--44.4), and Sputum production (17.2%, CI 10.8--26.4). Less common symptoms included hemoptysis (2.4%, CI 0.8--6.7), diarrhea (5.7%, CI 3.8--8.6), and nausea/vomiting (5.0%, CI 2.3--10.7) ([Table 2](#T2){ref-type="table"}).

###### 

Meta-analysis of comorbidities.

                           **Pooled frequency**   ***n/N*[^\*^](#TN1){ref-type="table-fn"}**   **Publication bias**   **Heterogeneity test**   
  ------------------------ ---------------------- -------------------------------------------- ---------------------- ------------------------ ------
  Smoking                  8.0 (2.3--13.6)        172/1,332                                    0.06                   100                      0.00
  Hypertension             18.5 (12.7--24.4)      306/1,800                                    0.98                   100                      0.00
  Cardiovascular disease   14.9 (6.0--23.8)       178/2,031                                    0.72                   100                      0.00
  Diabetes                 10.8 (8.3--13.3)       166/1,932                                    0.39                   100                      0.00
  Pulmonary disease        3.4 (0.8--6.0)         39/2,031                                     0.72                   100                      0.00
  Malignancies             2.8 (0.8--4.8)         33/1,816                                     0.74                   100                      0.00
  Chronic liver disease    8.1 (4.6--11.6)        29/546                                       0.45                   100                      0.00
  Renal disease            4.4 (0.24--8.6)        17/1,472                                     0.33                   100                      0.00

*n, number of patients with comorbidity; N, total number of patients*.

The most common comorbidities were hypertension (18.5%, CI 12.7--24.4), cardiovascular diseases (14.9%, CI 6.0--23.8), diabetes (10.8%, CI 8.3--13.3), chronic liver disease (8.1, CI 4.6--11.6) and smoking (8.0%, CI 2.3--13.6), respectively ([Table 3](#T3){ref-type="table"}).

###### 

Meta-analysis of clinical manifestations.

                      **Pooled frequency**   ***n/N*^\*^**   **Publication bias**   **Heterogeneity test**   
  ------------------- ---------------------- --------------- ---------------------- ------------------------ ------
  Fever               83.0 (77.5--87.6)      2,073/2,465     0.76                   86                       0.00
  Cough               65.2 (58.6--71.2)      1,689/2,515     0.80                   85                       0.00
  Dyspnea             27.4 (19.6--35.2)      477/2,014       0.42                   89                       0.00
  Myalgia/fatigue     34.7 (26.0--44.4)      742/1,938       0.60                   89                       0.00
  Sputum production   17.2 (10.8--26.4)      480/1,862       0.01                   89                       0.00
  Sore throat         14.5 (10.6--19.5)      224/1,577       0.88                   66                       0.00
  Headache            11.1 (7.7--15.7)       230/1,864       0.30                   74                       0.00
  Diarrhea            5.7 (3.8--8.6)         104/2,041       0.77                   66                       0.00
  Hemoptysis          2.4 (0.8--6.7)         20/1,339        0.77                   100                      0.00
  Anorexia            10.1 (1.0--57.2)       82/1,322        0.73                   98                       0.00
  Nausea/vomiting     5.0 (2.3--10.7)        65/1,563        0.90                   85                       0.00
  Dizziness           8.6 (2.5--26.0)        16/205          0.90                   65                       0.00
  Chest tightness     8.4 (2.5--26.0)        24/256          0.24                   78                       0.00
  Rhinorrhea          9.3 (2.2--31.0)        28/232          0.17                   88                       0.00
  Chills              14.3 (3.0--47.4)       12/111          NA                     86                       0.00

Lab Abnormalities and Complications
-----------------------------------

The most frequent abnormal laboratory findings in patients with COVID-19 were, respectively, elevated C-Reactive Protein (CRP) (72% CI 54.3--84.6), lymphopenia (50.1%, CI 38.0--62.4), elevated Lactate Dehydrogenase (LDH) (41%, CI 22.8--62.0), elevated serum aspartate aminotransferase (19.7%, CI 10.5--33.7), and thrombocytopenia (11.1%, CI 7.7--15.7) ([Table 4](#T4){ref-type="table"}). Among the confirmed COVID-19 subjects, 14.0% (CI, 6.7--29.0) had viremia. Impaired hepatic function with ALT levels \>47.25 U/L was seen in 13.3% (CI 3.2--41.0) of COVID-19 subjects. Acute cardiac injury with troponin levels \>28 pg/ml was seen in 12.4% (CI 6.2--23.2). Acute kidney injury was found in 5.5% (CI 1.3--20.8). Shock was reported in 4.0% (CI 1.6--12.0). Finally, 13.0% (CI 4.8--30.0) met the definition of acute respiratory distress syndrome (ARDS).

###### 

Meta-analysis of laboratory findings.

                           **Pooled frequency**   ***n/N*^\*^**   **Publication bias**   **Heterogeneity test**   
  ------------------------ ---------------------- --------------- ---------------------- ------------------------ ------
  Lymphopenia              50.1 (38.0--62.4)      1,122/1,853     0.08                   93                       0.00
  Lymphocytosis            33.5 (2.4--90.2)       55/93           NA                     88                       0.00
  Neutrophilia             29.7 (19.3--42.7)      60/191          0.51                   58.7                     0.08
  Leukopenia               28.0 (20.0--37.4)      544/1,798       0.89                   88                       0.00
  Leukocytosis             10.8 (5.8--19.1)       165/1,829       0.86                   92                       0.00
  Thrombocytopenia         11.1 (7.7--15.7)       343/1,393       0.00                   86                       0.00
  Anemia                   43.5 (30.3--57.7)      79/179          NA                     72                       0.00
  Decreased albumin        51.8 (2.0--98.0)       105/191         0.99                   96                       0.00
  High CRP                 72.0 (54.3--84.6)      918/1,681       0.02                   96                       0.00
  High LDH                 41.0 (22.8--62.0)      408/1,393       0.32                   94                       0.00
  High ESR                 79.7 (66.6--88.5)      143/179         NA                     69                       0.00
  High AST                 19.7 (10.5--33.7)      267/1,474       0.70                   93                       0.00
  High ALT                 14.6 (7.6--26.3)       191/1,290       0.99                   84.8                     0.00
  High creatinine kinase   14.1 (8.3--23.0)       142/1,453       0.20                   84                       0.00
  High bilirubin           7.9 (2.9--19.0)        95/1,278        0.96                   89                       0.00
  High creatinine          3.3 (1.2--9.1)         20/1,294        0.13                   74                       0.00
  High troponin I          2.4 (0.3--15.0)        1/41            NA                     0.00                     0.1

Radiological Characteristics
----------------------------

Chest X-Ray (CXR) and Chest CT scan were the most common imaging modalities used for the diagnosis of COVID-19. The pooled sensitivity of CT scan for detecting COVID-19 was 79.3%. The most common sites of the lung involvement based on chest CT scan were right lower lobe (76.2%, CI 57.8--82.5) followed by the left lower lobe (71.8%, CI 57.8--82.5). Most of the patients (74.8%) had bilateral involvement. The most common pattern of parenchymal involvement was ground-glass opacities (66.0%, CI 51.1--78.0). The Chest CT scan was reported normal in 20.7% of the patients with confirmed RT-PCR results ([Table 5](#T5){ref-type="table"}).

###### 

Meta-analysis of imaging findings.

  **CT Scan**               **Patterns**              **Pooled frequency**                                           ***n/N*[^\*^](#TN2){ref-type="table-fn"}**   **Publication bias**   **Heterogeneity test**          
  ------------------------- ------------------------- -------------------------------------------------------------- -------------------------------------------- ---------------------- ------------------------ ------ ------
  Location of involvement   Number of affected lobe   Unaffected                                                     20.7 (15.1--27.6)                            33/161                 0.18                     0.0    0.57
                                                      1 lobe                                                         14.8 (7.4--24.0)                             52/318                 0.22                     73     0.00
                                                      2 lobes                                                        9.5 (6.5--12.8)                              30/318                 0.32                     0.0    0.50
                                                      3 lobes                                                        11.7 (7.9--14.6)                             36/318                 0.64                     0.0    0.50
                                                      4 lobes                                                        15.8 (10.3--20.7)                            49/318                 0.90                     40     0.15
                                                      5 lobes                                                        37.2 (32.0--42.3)                            118/318                0.50                     30     0.22
                            Affected lobe (s)         RUL                                                            56.8 (50.6--62.8)                            145/255                0.12                     52     0.10
                                                      RML                                                            48.6 (42.5--54.8)                            124/255                0.07                     0.0    0.48
                                                      RLL                                                            76.2 (65.5--84.4)                            193/255                0.14                     64     0.03
                                                      LUL                                                            56.0 (47.1--64.7)                            153/255                0.12                     0.0    0.40
                                                      LLL                                                            71.8 (57.8--82.5)                            167/234                0.30                     76     0.01
                            Laterality                Uni lateral                                                    28.8 (16.6--45.2)                            62/205                 0.80                     77     0.01
                                                      Bi lateral                                                     70.6 (55.3--82.5)                            142/205                0.20                     74     0.01
  Pattern of involvement    Pattern of involvement    No involvement                                                 17.2 (11.4--25.0)                            193/1,080              0.42                     63.0   0.04
                                                      Both of GGO[^\*^](#TN2){ref-type="table-fn"} & consolidation   39.0 (28.1--51.0)                            57/142                 NA                       25     0.24
                                                      GGO without consolidation                                      66.0 (51.1--78.0)                            846/1,365              0.67                     90     0.00
                                                      Consolidation without GGO                                      9.4 (3.3--23.6)                              26/274                 0.21                     82     0.00
                            Laterality                Uni lateral                                                    21.8 (12.0--36.3)                            101/507                0.63                     87     0.00
                                                      Bi lateral                                                     74.8 (62.5--84.0)                            405/548                0.29                     84     0.00

*GGO, Ground Glass Opacities*.

Outcomes
--------

94.6% (CI 73.8--99.1) of the patients with severe COVID-19 were hospitalized. The pooled mortality rate of these patients was 6.6% (CI 2.8--15.0) ([Tables 6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}). Old age, male sex, presence of underlying diseases, higher level of D-dimer, lower level of fibrinogen and anti-thrombin, progressive radiographic deterioration on follow up CT scans, development of ARDS, and requirement of mechanical ventilation were all reported factors associated with increased mortality rate. As shown in [Table 8](#T8){ref-type="table"}, men had significantly higher mortality in the hospital compared to women (OR 3.4; 95% CI 1.2--9.1, *P* = 0.01). Although ICU admission was higher in men, the difference was not statistically significant. The mean duration between the time of hospitalization and death was 17.5 days with minimum and maximum periods of 14 and 21 days, respectively. The effects and summaries calculated using a random-effects model weighted by the study population is shown in [Figure 2](#F2){ref-type="fig"}.

###### 

Meta-analysis of complications.

                         **Pooled frequency**   ***n/N*^\*^**   **Publication bias**   **Heterogeneity test**   
  ---------------------- ---------------------- --------------- ---------------------- ------------------------ ------
  RNAemia                14.0 (6.7--29.0)       6/41            NA                     0.00                     1.00
  ARDS                   13.0 (4.8--30.0)       142/1,794       0.67                   96                       0.00
  Acute cardiac injury   12.4 (6.2--23.2)       28/243          0.83                   65                       0.03
  Acute kidney injury    5.5 (1.3--20.8)        34/1,441        0.58                   93                       0.00
  Liver failure          13.3 (3.2--41.0)       20/144          0.50                   84                       0.00
  Shock                  4.0 (1.6--12.0)        32/1,389        0.60                   86                       0.00
  Hospitalization        94.6 (73.8--99.1)      1,561/1,829     0.76                   98                       0.00

###### 

Meta-analysis of outcomes.

               **Pooled frequency**   ***n/N*^\*^**   **Publication bias**   **Heterogeneity test**   
  ------------ ---------------------- --------------- ---------------------- ------------------------ ------
  Discharged   52.7 (36.5--68.4)      486/948         0.44                   93                       0.00
  Death        6.6 (2.8--15.0)        111/2,026       0.50                   93                       0.00

###### 

Mortality and ICU admission in men vs. women in patients with COVID-19.

                                   **Pooled OR**    ***p*-value**   **Heterogeneity test**   
  -------------------------------- ---------------- --------------- ------------------------ -----
  Mortality in men vs. women       3.4 (1.2--9.1)   0.01            0.00                     0.6
  ICU admission in men vs. women   1.6 (0.7--3.2)   0.1             0.00                     0.5

![The pooled mortality rate of patients with COVID-19. Effects and summaries were calculated using a random-effects model weighted by study population.](fmed-07-00459-g0002){#F2}

Discussion {#s4}
==========

We evaluated the signs and symptoms, diagnostic modalities, therapeutic measures, and epidemiologic features of COVID-19 to have a better understanding of this pandemic caused by SARS-CoV-2. The pooled mortality rate of these patients was 6.6% overall. We detected several factors that contributed to a worsened outcome including old age, male sex, presence of underlying diseases, and abnormal laboratory finding such as an elevated D-Dimer. Although there was not a significant difference between male and female gender in ICU admissions, male gender showed a significantly higher in-hospital mortality rate.

D-Dimer \>1 μg/mL was identified as an associative factor that increased odds of in-hospital death in a study by Zhou et al. (*p* = 0.0033) ([@B43]).

Another significant finding in our analysis was the incidence of cardiac injury in 12.4% of the patients, which is a common event seen in a multitude of viral illnesses ([@B44]). Gao et al. observed that subjects with influenza (H7N9) and cardiac injury had an elevated risk of mortality (HR = 2.06) ([@B45]). In a study by Ludwig et al. which analyzed cardiac biomarkers in influenza patients, 24% of the subjects showed acute cardiac injury ≤30 days after influenza diagnosis and half of the injuries included myocardial infarctions ([@B46]). Although our analysis did not show increased mortality risk in patients with cardiac injury, these findings could indicate the potential need for identifying and optimizing cardiac risk factors in COVID-19 patients during the treatment period.

The mean duration between hospitalization and death was 17.5 days (range: 4--21 days), compared to 17.4 days in SARS ([@B47]). The overall mortality rate in this study was 6.6%, which is more than twice that was reported earlier ([@B20]). Though comparable mortality was reported by Li et al. (7%) and Qian et al. (8.9%) in their meta-analyses, a study by Rodriguez et al. showed a much higher death rate of 13.9% ([@B48]--[@B50]). On the other hand, a study from the Jiangsu province of China results showed a high cure rate equal to 96.67%. Although the main reason for very low mortality in this study remains unknown, measures including early recognition and centered-quarantine may be contributing factors ([@B51]).

Of note, the in-hospital mortality of males was significantly higher than that of females (OR 3.4; 95% CI 1.2--9.1, *P* = 0.01). A similar pattern of higher mortality in males has been reported in previous coronavirus outbreaks of SARS and MERS. Karlberg et al. also reported that the gender-based difference in mortality was higher in younger males (0--44 years) (RR = 2), compared to those of age group 45--74 (RR-1.45) ([@B52]). Similarly, the study by Alghamdi et al. showed that the case fatality rate in males was twice that of females in MERS (52 vs. 23%) ([@B6]). Although a gender-based difference in the immune response to infections has been suggested as a possible factor, other contributing factors including smoking history and severity of underlying comorbidities cannot be ruled out ([@B53]). This is especially of significance in China, where the prevalence of smoking among men (57.6%) is almost 10 times higher that of women (6.7%) ([@B54]). This difference in mortality opens the discussion for the need to treat COVID-19 more aggressively in males, including the possibility of earlier intubation and mechanical ventilation in this population. Cigarette Smokers showed to have a higher expression of Angiotensin converting enzyme 2 (ACE2) in lower airways. As it was discussed, ACE2 is the receptor for SARSCoV-2 in the lower respiratory tracts. This finding suggests that smokers are at a higher risk for COVID-19 ([@B55]). Therefore we emphasize on smoking cessation especially in the male group with COVID-19. Men smoke more than five times as much as women. (35% in males compared to 6% in females). Although this ratio varies in different countries, it is true that men smoke more in almost all countries ([@B56]). These findings can suggest part of the reason behind the significant higher mortality in males with COVID-19. Further investigations are needed to understand this phenomenon.

According to Xiaochen Li et al. male, elder age, leukocytosis, high LDH level, cardiac injury, hyperglycemia and chronic corticosteroid use were related to a higher risk of death in COVID-19. Male group counted for slightly more than half of all their patients (50.9%), however 56.9% of the severe COVID-19 cases were males compared to 45.2% females (*P* = 0.006). They showed that 19.2% of patients with severe COVID-19 were smokers ([@B57]).

Ruan et al. studied 68 deceased cases and 82 discharged ones to identify the clinical predictors of COVID-19 mortality, they found a significant difference among patients with Cardiovascular diseases (*p* \< 0.001), however, their study didn\'t show any significant difference in sex ratio between the death group and the discharge group. (*P* \< 0.43) ([@B58]).

Obesity is a risk factor for comorbid conditions such as cardiovascular diseases which are associated with a higher COVID-19 related deaths. Simonnet et al. showed that invasive mechanical ventilation was significantly associated with male sex (*p* \< 0.05) and Body Mass Index (BMI) (*p* \< 0.05), independent of age, diabetes, and hypertension ([@B59]). Previous studies had shown a low mortality rate in obese and morbid obese patients presenting with ARDS which is defined as obesity paradox. There is still more data required to identify whether this paradox is broken by COVID-19 ([@B60]).

According to Zirui Tay et al. there may be alleles on the location of *ACE2* on X-chromosome that confer resistance to COVID-19. This may explain the lower mortality among females. Additionally, estrogen and testosterone sex hormones can modulate the immune response. Therefore, the disease severity may vary based on the hormonal immunoregulation effect ([@B61]). In general testosterone have an immunosuppressive effect and estrogen enhances the immunity. Females are less susceptible to viral infections ([@B62]).

Recent studies have shown that estrogen upregulates *ACE2* in human atrial myocardium by modulating the local Renin angiotensin aldosterone system (RAAS). Apart from *ACE2, Toll-like receptor (TLR) 7* is also encoded on X-chromosome. TLR7 mediates several immune cell responses ([@B63]). Berghöfer et al. showed that *in vitro* exposure of peripheral blood mononuclear cells (PBMCs) to TLR7 ligands results in higher production of interferon-α (IFNα) in cells from females compared to the cells from males ([@B64]).

The mechanisms by which androgens such as testosterone decrease the immune response has not been fully understood. Rettew et al. evaluated the acute effect of testosterone through *in vitro* treatment of macrophages generated in absence of androgen. The result was a significant decrease in *TLR4* expression and sensitivity to a TLR4-specific ligand. *In vivo* removal of testosterone resulted in significantly increased TLR4 cell surface expression and higher sensitivity to endotoxin. This may indicate an important mechanism of testosterone immunosuppressive effect ([@B65]).

Similar to the sex-based differences in SARAS-CoV2, some studies related to SARS-CoV infection have shown a higher mortality and severity of the disease in males. Karlberg et al. showed a significantly higher case fatality rate in males compared females infected with SARS-CoV (*p* \< 0.0001) ([@B52]). Channappanavar et al. evaluated the susceptibility to SARS-CoV infection in male mice compared to the age-matched female group. Ovariectomy or estrogen receptor antagonist treatment of female mice showed increased mortality in the SARS-CoV infected mice indicating a protective effect of estrogen receptor signaling ([@B66]).

Although around 70% of health and social care workforce worldwide are women and they are in potential exposure to sick patients, most of the studies have shown a higher overall mortality among men with COVID-19. More research is needed to investigate how sex results in different outcomes during the COVID-19 pandemic ([@B63]).

This study has several limitations. Due to the rapidly emerging COVID-19 situation around the globe and the novelty of this coronavirus, there is still limited clinical data regarding diagnostic modalities and effective therapeutic measures. Most of the clinical findings were from observational studies. Future clinical trials and animal models are also required to have conclusive clinical information. More studies outside China are needed for comprehensive results that reflect COVID-19 epidemiology globally. Due to the lack of accurate reports of the new cases in different countries, the epidemiologic measures are also limited. As this pandemic is growing fast, future studies are needed for the evaluation of epidemiologic and clinical features of COVID-19.

Conclusion {#s5}
==========

COVID-19 has presented with a significant number of mortalities especially among the males around the world. The high rate of hospitalization and case fatality among hospitalized patients along with the lack of intensive care facilities necessitated the identification of the risk factors associated with severe disease and mortality. Males had a significant higher risk of mortality compared to females in our study which was higher than the previous reports from the studies done in China. The reason behind the gender and sex disparity in COVID-19 mortality is still unclear. COVID-19 has been an emerging, rapidly evolving situation. There is still a lot of unknown features of COVID-19 for the broad scientific community to study and identify the risk factors and possible causes of a worse outcome among these patients.

Future Direction {#s6}
================

Further studies are essential on the role of sex hormones on mortality in COVID-19. Moreover, social, lifestyle, and environmental factors should be investigated to understand gender difference in COVID-19 mortality. Studying risk factors associated with mortality can assist us to develop a precise prognostic tool and to personalize treatment in COVID-19.
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